Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Innovent Expands Adimab Partnership; Second mAb Partnership in a Week

publication date: Jun 13, 2016
Innovent Biologics, a fast-growing Suzhou biotech, has expanded its collaboration with Adimab, a mAb discovery company located in New Hampshire. Using its proprietary yeast-based discovery program, Adimab will generate IgGs or bispecifics for multiple targets identified by Innovent. Innovent will develop the drug candidates and retain global rights to them. Last week, Innovent announced a $120 million partnership -- also for bispecifics -- with EpimAb Biotherapeutics, a Shanghai startup. Innovent will own global rights to these candidates as well, though EpimAb will share in revenues and income from out-licensings. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital